Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01766713 · ClinicalTrials.gov registry record · Phase 2
Ezetimibe Versus Placebo in the Treatment of Non-alcoholic Steatohepatitis
A Phase 2 study of Non-alcoholic Steatohepatitis, sponsored by University of California, San Diego.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT01766713 is a Phase 2 study of Non-alcoholic Steatohepatitis that has completed, run by University of California, San Diego. The registered enrollment target is 50 participants, below the 292-participant average among 12 other Non-alcoholic Steatohepatitis trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01766713, a Phase 2 study of Non-alcoholic Steatohepatitis, has completed, sponsored by University of California, San Diego.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to see if the drug ezetimibe is a potential treatment for Nonalcoholic Steatohepatitis(NASH).
Conditions Studied
Interventions
- DRUG Ezetimibe
Study Locations (1)
California
- University of California, San Diego - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2013-01 |
| Est. Completion | 2014-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01766713
The ClinicalTrials.gov registry entry for NCT01766713 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 292-participant average among 12 other Non-alcoholic Steatohepatitis trials with a reported enrollment target (83% lower). The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-alcoholic Steatohepatitis appearing as the primary indexed condition, and to 1 intervention - of which Ezetimibe is the first listed.
NCT01766713 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT01766713 about?
NCT01766713 is a clinical study titled "Ezetimibe Versus Placebo in the Treatment of Non-alcoholic Steatohepatitis". The purpose of the study is to see if the drug ezetimibe is a potential treatment for Nonalcoholic Steatohepatitis(NASH).
What is the current status of trial NCT01766713?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2013-01. Estimated completion is 2014-09.
What conditions does trial NCT01766713 study?
This clinical trial studies the following conditions: Non-alcoholic Steatohepatitis.
What interventions are being tested in trial NCT01766713?
The interventions under investigation include: Ezetimibe (DRUG).
Who is sponsoring clinical trial NCT01766713?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01766713 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-alcoholic Steatohepatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
RECRUITING · Phase 2
-
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
COMPLETED · Phase 2
-
An Evaluation of the Safety and Efficacy of Nitazoxanide on Collagen Turnover in NASH Patients With Fibrosis
COMPLETED · Phase 2
-
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC-0602K in Patients With NASH
COMPLETED · Phase 2
-
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis
COMPLETED · Phase 2
-
Saroglitazar Magnesium in the Treatment of Non-Alcoholic Steatohepatitis
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.